King's College London

Plenty of biopharmaceutical firms continue to struggle to raise fresh capital under current financial market conditions with drug developer valuations still well below what they were a few years ago a

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. OrsoBio Splurges With Four Concurrent L

Atlas Venture added more fuel to its biotechnology start-up engine with a $450m fund announced on 3 March, which the venture capital firm will invest in new companies developing novel therapeutics and

Athenex Taps NCI TCRs For Solid Tumor Off-The-Shelf Therapy Athenex, Inc. announced a licensing agreement on 9 November with the US National Cancer Institute (NCI) to expand its development capabil